PDE4A and psoriasis vulgaris: In 2023, another network meta-analysis, including 13 randomized clinical trials involving 5274 patients, compared the efficacy and safety of Tyk2 and PDE4 inhibitors in treating moderate to severe plaque psoriasis [166].